Megan A. Smith (Australia)
Cancer Council New South Wales Cancer Research DivisionPresenter of 3 Presentations
Data and Monitoring (ID 1703)
Webcast
COMPASS-PLUS: EVALUATING THE PSYCHOLOGICAL IMPACT OF PRIMARY HPV SCREENING WITHIN THE AUSTRALIAN CERVICAL SCREENING PROGRAM (ID 775)
- Louiza S. Velentzis (Australia)
- Chloe J. Jennett (Australia)
- Sam Egger (Australia)
- Jo Waller (United Kingdom)
- Julia M. Brotherton (Australia)
- Maddison Sherrah (Australia)
- Megan A. Smith (Australia)
- Deborah Bateson (Australia)
- Rachel S. Skinner (Australia)
- Margaret Kelaher (Australia)
- Marion Saville (Australia)
- Karen Canfell (Australia)
Abstract
Introduction
In December 2017 Australia’s screening program transitioned to 5-yearly primary HPV screening with partial genotyping for women aged 25-74 years. HPV testing has a higher sensitivity for the detection of precancerous lesions. However, there is little evidence regarding the psychological effects of HPV screening. Compass-PLUS, a sub-study of Compass (randomised trial of primary HPV screening vs cytology) has been established to evaluate the psychological aspects of primary HPV screening in the context of the renewed program.
Methods
Compass-PLUS has a repeat cross-sectional survey design. Participants in the Compass trial are invited by email or text message to participate in the sub-study, shortly after receiving their screening result. Following consent, participants complete on-line questionnaires at baseline, 6 months, and 3 months after their one year, 2.5 years (cytology arm only) and 5 year Compass visit. The primary outcome is to evaluate anxiety and distress in women with different HPV and cytology results. Factors related to cervical screening outcomes and adherence, utility scores and other outcomes will also be investigated.
Results
Recruitment to Compass-PLUS commenced in June 2019. Within the first 3 months, a total of 525 women aged 25-39 years were invited, of whom 165 have consented (response rate of 31%). Based on data from the first 102 participants, 67% are in the HPV arm of Compass and 33% in the cytology arm (consistent with the 2:1 trial randomisation) which will enable comparisons between low, intermediate and high risk groups based on test results, in-line with the program. The majority of women were Australian-born (76%), married/registered partnership (56%), have a university degree/higher certificate (59%), live in a city (75%) and in the highest two quintiles of socioeconomic status (68%).
Conclusions
Compass-PLUS will inform the support of women who have high risk HPV test results and the successful long-term implementation of Australia’s screening program.